Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: This presentation aimed to address the effectiveness of botulinumtoxin-A (BoNT-A) for the management of melasma.

Introduction: Melasma is a common hyperpigmentary condition especially in individuals with dark-complexioned skin. The most well-known aggravating factor is ultraviolet (UV) exposure. Previous studies have been shown a beneficial effect of BoNT-A for the prevention and treatment of UVB-induced hyperpigmentation.

Materials / method: A pilot study was conducted in 14 patients with melasma. One side of each patient's face was treated with triple combination cream (4% hydroquinone, 0.05% tretinoin, 0.01% fluocinolone acetonide, TCC) for 12 weeks (monotherapy group), while the other side was treated with combined intradermal BoNT-A (2 sessions, baseline and week 12) and 12-week TCC application (combined group). Evaluations were performed at 2, 4, 8, 12, 16, 20, and 24 weeks with Visia®, Antera 3D®, Colorimeter®, MASI score on malar area (MASIm), GAIS score, and patient satisfaction.

Results: Fourteen subjects completed the study. A greater reduction of MASIm was observed in combined group when compared to the monotherapy group at 4 weeks (27.94 % vs 12.65 % reduction). Melasma recurrence was observed in monotherapy group after TCC discontinuation. At the end of the study, a higher patients satisfaction score was observed in the combined group when compared to monotherapy group. No serious adverse events were reported.

Conclusion: A combination of intradermal BONT-A injection and TCC demonstrated a beneficial effect in melasma treatment and prevention of melasma recurrence than TCC monotherapy.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): Botulinum toxin was supported by Merz Aesthetics. The supporter has no role in study design and conducting the study.

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: Reactive oxygen species (ROS) generated during melanogenesis make melanocytes particularly vulnerable to oxidative stress, influencing their survival and melanin synthesis. Oxidative stress, detected in melasma, triggers inflammatory cascades and melanogenesis, making antioxidants a promising therapeutic option.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability